GCT-21 - Testicular cancer genomics England Clinical Interpretation Partnership (GECIP): A genomic exploration of testicular germ cell tumours
Publication date: 2019Source: European Urology Supplements, Volume 18, Issue 4Author(s): A.M. Frangou, A. Cornish, B. Kinnersley, D.C. Wedge, A. Protheroe, M.J. Murray, C. Verrill
ConclusionsThe evidence from the review suggests that the burden of disease for testicular cancer survivors is overall low. Men who had surgical intervention and were treated for testicular cancer experienced minimal impact on their mental health status than the men who had chemotherapy or radiotherapy as part of their treatment modality.Implications for Cancer SurvivorsThere is a need to provide appropriate referrals to the relevant services, including psychosocial support, and the development of more adequate communication resources for men following treatment for testicular cancer.
This report describes a 21‐year‐old man who was refractory to chemotherapy and immunotherapy. Whole exome sequencing and low‐depth whole genome sequencing confirmed the KRAS gene amplification, which may lead to the tumor cells’ progression and proliferation. After discussion at the molecular tumor board, the patient was offered paclitaxel, carboplatin, and sorafenib (CPS) based on a phase III clinical trial of melanoma with KRAS gene copy gains. After treatment with CPS, the patient achieved excellent curative effects. Because of a nearly 50% frequency of KRAS amplification in chemotherapy‐refractory testicu...
Authors: Fung C, Dinh PC, Fossa SD, Travis LB Abstract Testicular cancer (TC) is the most common cancer among men aged 18 to 39 years. It is highly curable, with a 10-year relative survival approaching 95% due to effective cisplatin-based chemotherapy. Given the increasing incidence of TC and improved survival, TC survivors (TCS) now account for approximately 4% of all US male cancer survivors. They have also become a valuable cohort for adult-onset cancer survivorship research, given their prolonged survival. Commensurately, long-term treatment-related complications have emerged as important survivorship issues. T...
Authors: Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA Abstract Testicular cancer is relatively uncommon and accounts for 50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs. PMID: ...
TESTICULAR cancer is more common in younger men with men in their early 30s most likely to get the disease. Statistics state that six million men have never checked themselves and nearly half regularly forget to check. So how do you check for testicular cancer? Experts advise checking for symptoms at a certain time of day.
The updated version of Table 4 of original publication and the Compliance with ethical standards are given in this correction.
Men who regularly smoke cannabis increase their risk of developing testicular cancer, according to a study by US experts.
A new meta-analysis finds insufficient evidence of an association between marijuana use and cancer, with the exception of testicular cancer.Medscape Medical News
Conditions: Testicular Cancer; Colorectal Neoplasms Intervention: Diagnostic Test: Colonoscopy surveillance Sponsor: The Netherlands Cancer Institute Not yet recruiting